Dov Grossman is Co-Chair of the firm’s Patent Litigation practice.

For two decades, Dov Grossman has been litigating patent matters on behalf of some of the world’s largest biopharmaceutical companies to protect their most important products.  An accomplished trial lawyer with a background in chemistry—including medicinal chemistry—Dov has served as lead counsel in a variety of biopharmaceutical disputes, both in federal district court and before the Patent Trial and Appeal Board.  He has extensive experience litigating Hatch-Waxman disputes for successful branded products, from the pre-litigation phase through trial and appeal.  Dov has also represented clients in various brand v. brand disputes, both in the biotechnology space and involving small molecule patents.  Biopharmaceutical companies frequently rely on Dov to help coordinate global patent litigation involving patents in the U.S. and abroad.

In addition to pharmaceutical-related matters, Dov has litigated patent cases in the crop science, medical device and telecommunications industries.  He also has advised clients on the negotiation of patent licensing agreements, including as the lead outside attorney handling the negotiations.

Since 2021, Dov has been recognized as a leading intellectual property attorney by IAM Patent 1000: The World’s Leading Patent Professionals, and beginning in 2023, he has also been recognized by both Benchmark Litigation and Managing Intellectual Property for his work in the patent space. In July 2023, The National Law Journal recognized Dov as an Emerging Therapies/Life Sciences Trailblazer for his representation of Pfizer in inter partes review proceedings relating to Pfizer’s first gene therapy product.

Dov, who speaks Hebrew as well as English, grew up in Los Angeles.  Dov earned his J.D., with honors, from the University of Chicago, where he was articles editor for The University of Chicago Law Review and a member of the Order of the Coif.  Dov clerked for Judge William C. Bryson of the U.S. Court of Appeals for the Federal Circuit.  He received his A.B. in chemistry, magna cum laude, from Harvard University in 1997, and an M.Sc. in chemistry from the Weizmann Institute of Science in 1999.  Aspects of his Weizmann research were published in Letters in Peptide Science in 2002 (“Potentiating Vanadium-Evoked Glucose Metabolism by Novel Hydroxamate Derivatives”).  Dov joined Williams & Connolly in 2004.

Representative Experience

  • Lead counsel for Bayer in Hatch-Waxman litigation and an inter partes review proceeding involving the anti-cancer medication Stivarga®.
  • Co-lead trial counsel in a Hatch-Waxman trial in the District of Delaware relating to Bayer’s erectile dysfunction medication vardenafil (marketed as Levitra® and Staxyn®).  The Court issued a decision in favor of Bayer on its compound patent at the close of trial.
  • Lead counsel for Bayer in multiple Hatch-Waxman cases related to the factor Xa inhibitor Xarelto®.  Dov also served as lead counsel in multiple inter partes review challenges to patents protecting Xarelto®.  He was also trial counsel in earlier Hatch-Waxman cases related to Xarelto®. 
  • Lead counsel for Bayer CropScience and Monsanto in patent litigation in the District of Delaware, as well as for three co-pending inter partes review proceedings.
  • Lead counsel for Pfizer in brand v. brand inter partes review proceedings involving gene therapy patents. The Patent Trial and Appeals Board issued three final written decisions in Pfizer’s favor.
  • Lead counsel for patent owner President and Fellows of Harvard College in IPR proceedings against petitioner 10x Genomics, Inc. related to methods for detecting nucleic acids.
  • Trial counsel in Hatch-Waxman litigation related to Eli Lilly’s Alimta® product, resulting in multiple victories for the patentee that were upheld on appeal.  Dov has also litigated multiple inter partes review proceedings related to Alimta®, resulting in two final written decisions of the Patent Trial and Appeals Board upholding validity.  The decisions were affirmed on appeal.
  • Co-lead counsel for AstraZeneca in Hatch-Waxman litigation involving the anti-cancer medication Tagrisso®.
  • Lead counsel in Hatch-Waxman litigation relating to Bayer’s Astepro® Allergy.
  • Counsel for AstraZeneca in brand v. brand patent litigation and co-pending inter partes review proceedings related to anti-diabetes treatments.
  • Trial counsel for two Hatch-Waxman trials related to moxifloxacin, the antibiotic active ingredient in Bayer’s Avelox® product and Alcon’s Vigamox® eye drops.  Both cases were resolved in favor of the patentee.
  • Lead outside counsel negotiating a portfolio cross-license agreement between suppliers of electronics components.
  • Representing a client in a major international patent licensing arbitration, which was tried before a three-member panel.
  • Counsel for AstraZeneca in brand v. brand patent litigation related to the anti-cancer medication Calquence®.
  • Counsel for Bayer in multiple Hatch-Waxman cases involving the anti-cancer medication Nexavar®.
  • Counsel for Alcon in Hatch-Waxman litigation involving Travatan Z® eye drops.




"Emerging Therapies/Life Sciences Trailblazer," The National Law Journal, 2023

"IP Star," Managing Intellectual Property, 2023-2024

“Leading Patent Litigation Attorney,” IAM Patent 1000, 2021-2024

"Litigation Star," Benchmark Litigation, 2023-2024


back to top